Table 2 Sensitivity (%) of PRRSV Ab ELISAs at each sampling point (95% confidence interval)
Study day | 0 | 3 | 7 | 10 | 14 |
|---|---|---|---|---|---|
Group V | |||||
IDEXX | 0 (0–30) | 0 (0–30) | 0 (0–30) | 80 (44–98) | 100 (69–100) |
INgezim | 90 (60–98) | 70 (35–93) | 100 (69–100) | 100 (69–100) | 100 (69–100) |
HIPRA A/S | 20 (3–56) | 20 (3–56) | 10 (0–45) | 50 (19–81) | 50 (19–81) |
HIPRA E/S | 0 (0–30) | 0 (0–30) | 0 (0–30) | 20 (3–56) | 20 (3–56) |
QIAGEN | 0 (0–30) | 0 (0–30) | 0 (0–30) | 80 (44–98) | 100 (69–100) |
AJ | 0 (0–30) | 0 (0–30) | 20 (3–56) | 70 (35–93) | 80 (44–98) |
Group N | |||||
IDEXX | n.d. | 0 (0–30) | 0 (0–30) | 70 (35–93) | 90 (60–98) |
INgezim | n.d. | 0 (0–30) | 0 (0–30) | 100 (69–100) | 100 (69–100) |
HIPRA A/S | n.d. | 0 (0–30) | 0 (0–30) | 0 (0–0) | 30 (7–65) |
HIPRA E/S | n.d. | 0 (0–30) | 0 (0–30) | 0 (0–0) | 0 (0–0) |
QIAGEN | n.d. | 0 (0–30) | 0 (0–30) | 40 (12–74) | 90 (60–98) |
AJ | n.d. | 0 (0–30) | 0 (0–30) | 10 (0–45) | 60 (26–88) |